| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
313.64(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
30,300 |
| Total Buy Value |
$0 |
$0 |
$863 |
$132,633 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gill John |
President and CEO |
• • – |
2015-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
612,244 |
612,244 |
|
- |
|
| Macneill Philip |
CFO |
• – – |
2015-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Macneill Philip |
CFOOfficer |
• – – |
2015-05-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| St Peter Steven |
Director |
– • – |
2015-03-19 |
4 |
B |
$1.65 |
$41,213 |
D/D |
25,000 |
25,000 |
2.39 |
- |
|
| Jones Jeffrey Michael |
COOOfficer |
• – – |
2015-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,544 |
|
- |
|
| Jones Jeffrey Michael |
COO |
• – – |
2015-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
27,544 |
|
- |
|
| Chang Linda L |
SVP, CFO & Secretary |
• – – |
2015-01-07 |
4 |
AS |
$2.10 |
$62,160 |
D/D |
(29,600) |
30,000 |
|
- |
|
| Chang Linda L |
SVP, CFO & Secretary |
• – – |
2015-01-07 |
4 |
OE |
$1.13 |
$33,448 |
D/D |
29,600 |
59,600 |
|
- |
|
| Frohlich Phil |
10% Owner |
– – • |
2014-09-22 |
4 |
B |
$1.54 |
$23,185 |
I/I |
15,000 |
7,981,035 |
1.5 |
- |
|
| Frohlich Phil |
10% Owner |
– – • |
2014-08-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,966,035 |
|
- |
|
| Frohlich Phil |
10% Owner |
– – • |
2013-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,244,835 |
|
- |
|
| Richman Eric I |
See Remarks |
• • – |
2012-03-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,500) |
176,822 |
|
- |
|
| Cook Francesca M |
SVP, Policy & Govt Affairs |
• – – |
2012-01-21 |
4 |
D |
$1.30 |
$3,977 |
D/D |
(3,059) |
37,631 |
|
- |
|
| Runge Jeffrey W. |
Director |
– • – |
2011-12-12 |
4 |
B |
$1.30 |
$26,000 |
I/I |
20,000 |
20,000 |
2.1 |
- |
|
| Richman Eric I |
President & CEO |
• • – |
2011-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
199,322 |
|
- |
|
| Fuerst Thomas Richard |
SVP, Chief Scientific Officer |
• – – |
2011-11-22 |
4 |
B |
$1.27 |
$6,350 |
D/D |
5,000 |
15,000 |
2.74 |
- |
|
| Chang Linda L |
SVP & CFO |
• – – |
2011-11-16 |
4 |
B |
$1.38 |
$13,842 |
D/D |
10,000 |
30,000 |
2.74 |
- |
|
| Chang Linda L |
SVP & CFOOfficer |
• – – |
2011-11-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
- |
|
| Fuerst Thomas Richard |
EVP, Chief Scientific Officer |
• – – |
2011-11-10 |
4 |
B |
$1.51 |
$15,098 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Richman Eric I |
President and CEO |
• • – |
2011-11-10 |
4 |
B |
$1.50 |
$15,025 |
I/I |
10,000 |
2,500 |
2.58 |
- |
|
| Karp Jordan P |
SVP, General Counsel |
• – – |
2011-11-10 |
4 |
B |
$1.51 |
$15,064 |
I/I |
10,000 |
10,000 |
1.99 |
- |
|
| Richman Eric I |
See Remarks |
• • – |
2011-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
124,322 |
|
- |
|
| Karp Jordan P |
SVP, General Counsel |
• – – |
2011-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
29,792 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-08-25 |
4/A |
B |
$0.00 |
$0 |
D/D |
0 |
0 |
2.31 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2011-08-25 |
4 |
B |
$0.70 |
$11,760 |
D/D |
16,800 |
1,055,413 |
2.39 |
- |
|
417 Records found
|
|
Page 11 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (1.54%) 
